statistiche ricercatore

Continente	#
NA - Nord America	1840
EU - Europa	1041
AS - Asia	882
SA - Sud America	17
OC - Oceania	16
AF - Africa	11
Continente sconosciuto - Info sul continente non disponibili	10
Totale	3817

Nazione	#
US - Stati Uniti d'America	1784
CN - Cina	554
IT - Italia	326
DE - Germania	136
FR - Francia	96
JP - Giappone	92
GB - Regno Unito	80
IN - India	60
IE - Irlanda	57
SE - Svezia	50
CA - Canada	44
ES - Italia	41
KR - Corea	33
PL - Polonia	32
FI - Finlandia	30
BE - Belgio	28
NL - Olanda	27
VN - Vietnam	27
UA - Ucraina	26
TR - Turchia	22
HK - Hong Kong	21
TW - Taiwan	20
AT - Austria	19
GR - Grecia	16
AU - Australia	13
PT - Portogallo	13
MX - Messico	11
SG - Singapore	10
CZ - Repubblica Ceca	9
DK - Danimarca	9
RO - Romania	9
TH - Thailandia	9
BR - Brasile	8
CH - Svizzera	8
NO - Norvegia	7
EU - Europa	6
HU - Ungheria	6
IL - Israele	6
MY - Malesia	6
SN - Senegal	6
ID - Indonesia	5
IR - Iran	5
RU - Federazione Russa	5
SI - Slovenia	5
AP - ???statistics.table.value.countryCode.AP???	4
CY - Cipro	4
AR - Argentina	3
CO - Colombia	3
NZ - Nuova Zelanda	3
EG - Egitto	2
LB - Libano	2
RS - Serbia	2
SA - Arabia Saudita	2
SK - Slovacchia (Repubblica Slovacca)	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
CU - Cuba	1
DZ - Algeria	1
EC - Ecuador	1
EE - Estonia	1
LT - Lituania	1
PE - Perù	1
PH - Filippine	1
TN - Tunisia	1
TZ - Tanzania	1
UY - Uruguay	1
Totale	3817

Nome	#
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer	1019
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations	969
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer	321
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer	304
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer	258
Met-driven invasive growth involves transcriptional regulation of Arhgap12	178
Ron kinase transphosphorylation sustains MET oncogene addiction	149
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis	145
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer	143
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.	128
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer	95
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.	86
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.	61
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer	58
Totale	3914

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2017/2018	214	0	0	0	0	0	0	0	57	74	39	25	19
2018/2019	510	39	27	25	28	30	16	20	49	26	58	123	69
2019/2020	761	59	43	44	88	38	79	58	78	88	62	69	55
2020/2021	775	48	25	50	66	63	61	92	47	71	91	58	103
2021/2022	857	85	79	102	112	43	45	75	54	66	51	84	61
2022/2023	420	60	71	39	56	50	90	53	1	0	0	0	0
Totale													3914

CINECA IRIS Institutional Research Information System